EA3: A softmax algorithm for evidence appraisal aggregation
- PMID: 34138908
- PMCID: PMC8211196
- DOI: 10.1371/journal.pone.0253057
EA3: A softmax algorithm for evidence appraisal aggregation
Abstract
Real World Evidence (RWE) and its uses are playing a growing role in medical research and inference. Prominently, the 21st Century Cures Act-approved in 2016 by the US Congress-permits the introduction of RWE for the purpose of risk-benefit assessments of medical interventions. However, appraising the quality of RWE and determining its inferential strength are, more often than not, thorny problems, because evidence production methodologies may suffer from multiple imperfections. The problem arises to aggregate multiple appraised imperfections and perform inference with RWE. In this article, we thus develop an evidence appraisal aggregation algorithm called EA3. Our algorithm employs the softmax function-a generalisation of the logistic function to multiple dimensions-which is popular in several fields: statistics, mathematical physics and artificial intelligence. We prove that EA3 has a number of desirable properties for appraising RWE and we show how the aggregated evidence appraisals computed by EA3 can support causal inferences based on RWE within a Bayesian decision making framework. We also discuss features and limitations of our approach and how to overcome some shortcomings. We conclude with a look ahead at the use of RWE.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures





Similar articles
-
Examining the Use of Real-World Evidence in the Regulatory Process.Clin Pharmacol Ther. 2020 Apr;107(4):843-852. doi: 10.1002/cpt.1658. Epub 2019 Nov 14. Clin Pharmacol Ther. 2020. PMID: 31562770 Free PMC article. Review.
-
A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks.Ther Innov Regul Sci. 2024 Nov;58(6):1042-1052. doi: 10.1007/s43441-024-00680-z. Epub 2024 Jul 25. Ther Innov Regul Sci. 2024. PMID: 39060838
-
The use of real-world data/evidence in regulatory submissions.Contemp Clin Trials. 2021 Oct;109:106521. doi: 10.1016/j.cct.2021.106521. Epub 2021 Jul 31. Contemp Clin Trials. 2021. PMID: 34339865
-
Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact.Value Health. 2021 Sep;24(9):1241-1244. doi: 10.1016/j.jval.2021.03.020. Epub 2021 Jun 26. Value Health. 2021. PMID: 34452702
-
Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness.Clin Pharmacol Ther. 2022 Jan;111(1):150-154. doi: 10.1002/cpt.2272. Epub 2021 Jul 2. Clin Pharmacol Ther. 2022. PMID: 33891318 Review.
Cited by
-
Fast Methods for Drug Approval: Research Perspectives for Pandemic Preparedness.Int J Environ Res Public Health. 2023 Jan 29;20(3):2404. doi: 10.3390/ijerph20032404. Int J Environ Res Public Health. 2023. PMID: 36767769 Free PMC article.
-
Application for Recognizing Sign Language Gestures Based on an Artificial Neural Network.Sensors (Basel). 2022 Dec 15;22(24):9864. doi: 10.3390/s22249864. Sensors (Basel). 2022. PMID: 36560231 Free PMC article.